Insider Trading Alert - MNTA, CSCO And ANSS Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 21, 2014, 140 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $401.00 to $744,000,000.00.

Highlighted Stocks Traded by Insiders:

Momenta Pharmaceuticals (MNTA) - FREE Research Report

Wheeler Craig A, who is President at Momenta Pharmaceuticals, sold 1,688 shares at $12.08 on May 21, 2014. Following this transaction, the President owned 376,164 shares meaning that the stake was reduced by 0.45% with the 1,688-share transaction.

Kaundinya Ganesh Venkataraman, who is Senior V.P., Research at Momenta Pharmaceuticals, sold 227 shares at $12.08 on May 21, 2014. Following this transaction, the Senior V.P., Research owned 394,648 shares meaning that the stake was reduced by 0.06% with the 227-share transaction.

Shea Richard P, who is Svp, Cfo at Momenta Pharmaceuticals, sold 227 shares at $12.08 on May 21, 2014. Following this transaction, the Svp, Cfo owned 179,074 shares meaning that the stake was reduced by 0.13% with the 227-share transaction.

Bishop John E, who is Senior VP, Pharmaceutical Scie at Momenta Pharmaceuticals, sold 227 shares at $12.08 on May 21, 2014. Following this transaction, the Senior VP, Pharmaceutical Scie owned 110,625 shares meaning that the stake was reduced by 0.2% with the 227-share transaction.

Leicher Bruce, who is SVP & General Counsel at Momenta Pharmaceuticals, sold 227 shares at $12.08 on May 21, 2014. Following this transaction, the SVP & General Counsel owned 127,774 shares meaning that the stake was reduced by 0.18% with the 227-share transaction.

Roach James M., who is Senior VP, Development and Chi at Momenta Pharmaceuticals, sold 250 shares at $12.08 on May 21, 2014. Following this transaction, the Senior VP, Development and Chi owned 104,070 shares meaning that the stake was reduced by 0.24% with the 250-share transaction.

The shares most recently traded at $11.98, down $0.10, or 0.83% since the insider transaction. Historical insider transactions for Momenta Pharmaceuticals go as follows:

  • 4-Week # shares sold: 2,753
  • 12-Week # shares sold: 3,513
  • 24-Week # shares sold: 77,436

The average volume for Momenta Pharmaceuticals has been 1.0 million shares per day over the past 30 days. Momenta Pharmaceuticals has a market cap of $620.8 million and is part of the health care sector and drugs industry. Shares are down 34.05% year-to-date as of the close of trading on Wednesday.

Momenta Pharmaceuticals, Inc., a biotechnology company, is engaged in the structural characterization, process engineering, and biologic systems analysis of complex molecules in the areas of complex generics, biosimilars, and novel drugs. Currently, there are 3 analysts who rate Momenta Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MNTA - FREE

TheStreet Quant Ratings rates Momenta Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Momenta Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Cisco Systems (CSCO) - FREE Research Report

Elfrink Wim, who is EVP, Chief Globalisation Ofr at Cisco Systems, sold 2,000 shares at $24.40 on May 21, 2014. Following this transaction, the EVP, Chief Globalisation Ofr owned 253,133 shares meaning that the stake was reduced by 0.78% with the 2,000-share transaction.

The shares most recently traded at $24.41, up $0.01, or 0.04% since the insider transaction. Historical insider transactions for Cisco Systems go as follows:

  • 4-Week # shares sold: 38,271
  • 12-Week # shares sold: 38,271
  • 24-Week # shares sold: 49,847

The average volume for Cisco Systems has been 40.2 million shares per day over the past 30 days. Cisco Systems has a market cap of $124.2 billion and is part of the technology sector and computer hardware industry. Shares are up 9.14% year-to-date as of the close of trading on Wednesday.

Cisco Systems, Inc. designs, manufactures, and sells Internet protocol (IP) and other products related to the communications and information technology industry worldwide. The stock currently has a dividend yield of 3.15%. The company has a P/E ratio of 12.9. Currently, there are 18 analysts who rate Cisco Systems a buy, 1 analyst rates it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CSCO - FREE

TheStreet Quant Ratings rates Cisco Systems as a buy. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Cisco Systems Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Ansys (ANSS) - FREE Research Report

Fredberg Joshua, who is Vice President, Marketing at Ansys, sold 3,500 shares at $75.00 on May 21, 2014. Following this transaction, the Vice President, Marketing owned 7,367 shares meaning that the stake was reduced by 32.21% with the 3,500-share transaction.

The shares most recently traded at $74.53, down $0.47, or 0.63% since the insider transaction. Historical insider transactions for Ansys go as follows:

  • 4-Week # shares sold: 6,356
  • 12-Week # shares sold: 29,707
  • 24-Week # shares sold: 29,707

The average volume for Ansys has been 547,700 shares per day over the past 30 days. Ansys has a market cap of $6.8 billion and is part of the technology sector and computer software & services industry. Shares are down 15.33% year-to-date as of the close of trading on Wednesday.

ANSYS, Inc. develops and markets engineering simulation software and services used by engineers, designers, researchers, and students in the aerospace, automotive, manufacturing, electronics, biomedical, energy, and defense industries, as well as academia worldwide. The company has a P/E ratio of 27.9. Currently, there are 4 analysts who rate Ansys a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ANSS - FREE

TheStreet Quant Ratings rates Ansys as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Ansys Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Deutsche Bank Plans 'Significant' Job Cuts as Q1 Profits Slump

Deutsche Bank Plans 'Significant' Job Cuts as Q1 Profits Slump

Boeing Is Back to Cruising Altitude; GM Gets Assist From Amazon -- ICYMI

Boeing Is Back to Cruising Altitude; GM Gets Assist From Amazon -- ICYMI

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Dow and S&P 500 Finish Higher Amid Strong Corporate Earnings

Dow and S&P 500 Finish Higher Amid Strong Corporate Earnings